Clinical trials: Vinorelbine
Neoplasms, Breast
Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects
This is an open-label, single-arm, multi-center, Phase II study to determine the activity of vinorelbine plus lapatinib in either first- or second-line setting in women with ErbB2 overexpressing metastatic breast cancer (MBC).
- Trial name
- NCT00709618
- Testing
- Lapatinib, Vinorelbine
- Where
- 22 sites in United States
- Volunteers
- 44 people
- Sponsor
- GlaxoSmithKline
NSCLC, SBRT
SBRT in Multi-metastatic NSCLC Patients Which Are Pan-negative for Driver Mutations
This protocol is a phase II multi-center randomized controlled trial (RCT) evaluating the efficacy of SBRT in multi-metastatic NSCLC patients who are pan-negative for driver mutations.
- Conditions
- NSCLC, SBRT, GM-CSF
- Trial name
- NCT02940990
- Testing
- SBRT concurrent with GM-CSF, two-drug chemotherapy containing platinum, including carboplatin/Cisplatin + pemetrexed/docetaxel/paclitaxel/etoposide/gemcitabine/vinorelbine/albumin-bound paclitaxel
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Chest Hospital
Non Small Cell Lung Cancer (NSCLC)
Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)
The purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with advanced non small cell lung cancer who did not received prior…
- Trial name
- FLEX (NCT00148798)
- Testing
- cetuximab + cisplatin + vinorelbine, cisplatin + vinorelbine
- Where
- 118 sites in Argentina, Australia and 26 more
- Volunteers
- 1,861 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Prostate Cancer
Combination Chemotherapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006114
- Testing
- mitoxantrone hydrochloride, vinorelbine tartrate
- Where
- 10 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
NSCLC
Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation
This study will be performed as a local multicenter, randomized, phase III clinical study. It will compare the adjuvant chemotherapy in Stage IB-IIIA NSCLC with common EGFR mutation (Exon 19 deletion or L858R) who underwent total…
- Trial name
- NCT02795884
- Testing
- intercalation therapy using pemetrexed, cisplatin and erlotinib, Vinorelbine, cisplatin
- Sponsor
- Yonsei University
Breast Neoplasms
Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer
The primary objective of this study is to explore the efficacy and safety of adaptive therapy in the treatment of advanced breast cancer progressive after standard treatment.
- Trial name
- NCT07088263
- Testing
- Gemcitabine, Vinorelbine, Eribulin, or Utidelone
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Sun Yat-sen University
Non-small Cell Lung Cancer
Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer
This study was designed to determine whether adjuvant vinorelbine plus cisplatin and endostar prolongs overall survival compare to vinorelbine plus cisplatin alone among patients with completely resected IB-IIIA non-small-cell…
- Trial name
- NCT00576914
- Testing
- recombinant human endostatin
- Where
- China
- Volunteers
- 1,108 people
- Sponsor
- Chinese Academy of Sciences
Lung Neoplasm
Oral Vinorelbine and Cisplatin and Concurrent Radiotherapy After Induction Chemotherapy in Locally Advanced NSCLC.
Our aim is to conducted a multicenter phase II trial of the cisplatin-oral vinorelbine -radiotherapy combination after induction chemotherapy with cisplatin-docetaxel in patient with NSCLC.
- Trial name
- VINCR (NCT00295672)
- Testing
- Vinorelbine
- Where
- 6 sites in France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Brest
Malignant Pleural Mesothelioma
Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients
This is a multicenter retrospective analysis .The aim of the present study is to investigate the molecular predictors of vinorelbine response in tumor samples of a series of MPM patients and evaluate the possible impact on…
- Trial name
- NCT01865045
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Armando Santoro, MD
Neoplasms
BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours
To identify the Maximum Tolerated Dose (MTD) of afatinib in combination with vinorelbine i.v. by assessment of Dose Limiting Toxicities (DLT); To assess safety and anti-tumour efficacy and determine pharmacokinetic…
- Trial name
- NCT01214616
- Testing
- afatinib 20mg, afatinib 40mg, vinorelbine IV 25 or 20mg/m2
- Where
- 4 sites in Japan
- Volunteers
- 17 people
- Sponsor
- Boehringer Ingelheim
Breast Neoplasms
Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast Cancer
Endostatin has been widely applied for the clinical treatment of partial primary and metastatic solid tumors. Endostatin combined with chemotherapy has achieved favorable progression in the treatment of non-small cell lung cancer…
- Trial name
- NCT02489409
- Testing
- EndostarTM Injection, Gemcitabine, Navelbine
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xinjiang Medical University
Mesothelioma
An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma
A clinical study to assess if a new investigational drug is effective in treating malignant mesothelioma, compared to a chemotherapy treatment (Navelbine®).
- Trial name
- NCT00597116
- Testing
- Vinorelbine, Vandetanib
- Where
- 6 sites in Germany, Switzerland
- Volunteers
- 25 people
- Sponsor
- Genzyme, a Sanofi Company
Non-Small Cell Lung Cancer
Effect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy
The primary purpose of the study is to investigate if daily treatment with celecoxib, an inhibitor of cyclooxygenase-2, can prolong survival in patients with advanced non-small cell lung cancer who receive anticancer chemotherapy…
- Trial name
- CYCLUS (NCT00300729)
- Testing
- Celecoxib
- Where
- 13 sites in Sweden
- Volunteers
- 319 people
- Sponsor
- University Hospital, Linkoeping
Her2-negative Metastatic Breast Cancer, Her2-negative Locally Advanced Breast Cancer
Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer
The purpose of this study is Examination of the superiority of a combination of vinorelbine with the mTOR Inhibitor Everolimus vs. vinorelbine monotherapy for second-line treatment in advanced breast cancer.
- Trial name
- VicTORia (NCT01520103)
- Testing
- Vinorebine, Everolimus, Vinorelbine
- Where
- Germany
- Volunteers
- 139 people
- Sponsor
- AIO-Studien-gGmbH
Advanced Breast Cancer, HER2-positive Breast Cancer
A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer
This is a randomized, open-label, two-arm, phase III trial in Germany to investigate whether vinorelbine-based triple combination presents a less toxic treatment option than docetaxel-based triple combination in patients with…
- Trial name
- ATTILA (NCT03811418)
- Testing
- Trastuzumab, Pertuzumab, Vinorelbine
- Where
- Germany
- Sponsor
- iOMEDICO AG
Carcinoma, Non-Small-Cell Lung, Metastatic Lung Cancer
Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)
AIO-YMO/TRK-0416 (DURATION) is a open-label, treatment stratified and randomized phase II study of Durvalumab, frail or elderly patients with metastatic non-squamous NSCLC with no targetable molecular alterations (EGFRwt…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Metastatic Lung Cancer, Non Small Cell Lung Cancer, Lung Adenocarcinoma Metastatic
- Trial name
- DURATION (NCT03345810)
- Testing
- Durvalumab, Vinorelbine, Gemcitabine
- Where
- 30 sites in Germany
- Volunteers
- 200 people
- Sponsor
- AIO-Studien-gGmbH
Bladder Cancer, Cervical Cancer
Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy with may kill more tumor cells.
- Conditions
- Bladder Cancer, Cervical Cancer, Endometrial Cancer, Vaginal Cancer
- Trial name
- NCT00002949
- Testing
- paclitaxel, vinorelbine tartrate, radiation therapy
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Chicago
Breast Cancer
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer
This research study is studying a combination of drugs as a possible treatment for breast cancer. The drugs involved in this study are: Group A: Trastuzumab (Herceptin) + Vinorelbine (Navelbine) Group B: Trastuzumab + Vinorelbine…
- Trial name
- NCT03414658
- Testing
- Vinorelbine, Trastuzumab, Avelumab
- Where
- 17 sites in United States
- Volunteers
- 100 people
- Sponsor
- Adrienne G. Waks
Stage IV, NSCLC, Lung Neoplasms
The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial
This is a randomized phase III trial that will randomize elderly patients(70 years of age and older) who are not considered eligible for standard doublet or triplet regimens.
- Conditions
- Stage IV, NSCLC, Lung Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic
- Trial name
- EPIC (NCT03402048)
- Testing
- Carboplatin, Gemcitabine, Pemetrexed
- Where
- 28 sites in Italy
- Volunteers
- 567 people
- Sponsor
- University of Turin, Italy
Breast Cancer
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
The proposed trial provides a unique opportunity in that it combines genomic, proteomic, and pharmacogenomic assessments in patients receiving the most commonly used chemotherapies for advanced breast cancer.
- Trial name
- NCT00235235
- Testing
- Biopsy, Serum Collection, Urine Collection
- Where
- 11 sites in United States, Peru
- Volunteers
- 80 people
- Sponsor
- Hoosier Cancer Research Network